Ceftazidim / Avibactam (Zavicefta®) – Bacterial infections, multiple indications


Start date 01.05.2022
Resolution 03.11.2022
INN Ceftazidim / Avibactam
Brand name Zavicefta®
Pharm. company Pfizer Pharma GmbH
G-BA procedure ID 2022-05-01-D-816
ATC code J01DD52
Therapeutic area Infectious diseases
Reason for procedure Initial assessment – Reserve antibiotic
Regulatory status Reserve antibiotic

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Zavicefta is used in adults and paediatric patients from the age of 3 months of age for the treatment of the following infections:

Complicated intra-abdominal infections (cIAI).

Complicated urinary tract infections (cUTI), including pyelonephritis

Nosocomial pneumonia (HAP), including ventilator-associated pneumonia (VAP),

Treatment of adult patients with bacteraemia related or suspected to one of the above suspected association with any of the above infections

Subpopulation Indication Comparator
a) Complicated intra-abdominal infections (cIAI)
d) Adult patients with bacteraemia associated with or suspected of being associated with complicated intra-abdominal infections (cIAI). suspected association with complicated intra-abdominal infections (cIAI), with complicated urinary tract infections (cUTI), including pyelonephritis, or with nosocomial pneumonia (HAP), including ventilator-associated pneumonia (VAP).

9. Associated procedures

<< List of all resolutions

Log in to read more ...

The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.